Details of the Drug

General Information of Drug (ID: DMGWDCW)

Drug Name

TAK-103

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

CAR-T cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05164666) An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.